Using CRISPR gene editing, a team from Children’s Hospital of Philadelphia (CHOP) and Penn Medicine have thwarted a lethal lung disease in an animal model in which a harmful mutation causes death within hours after birth.
This proof-of-concept study, published today in Science Translational Medicine, showed that in uteroediting could be a promising new approach for treating lung diseases before birth.
“The developing fetus has many innate properties that make it an attractive recipient for therapeutic gene editing,” said study co-leader William H. Peranteau, MD, an investigator at CHOP’s Center for Fetal Research, and a pediatric and fetal surgeon in CHOP’s Center for Fetal Diagnosis and Treatment. “Furthermore, the ability to cure or mitigate a disease via gene editing in mid- to late gestation before birth and the onset of irreversible pathology is very exciting. This is particularly true for diseases that affect the lungs, whose function becomes dramatically more important at the time of birth.”
The lung conditions the team is hoping to solve — congenital diseases such as surfactant protein deficiency, cystic fibrosis, and alpha-1 antitrypsin — are characterized by respiratory failure at birth or chronic lung disease with few options for therapies. About 22 percent of all pediatric hospital admissions are because of respiratory disorders, and congenital causes of respiratory diseases are often lethal, despite advances in care and a deeper understanding of their molecular causes. Because the lung is a barrier organ in direct contact with the outside environment, targeted delivery to correct defective genes is an attractive therapy.
“We wanted to know if this could work at all,” said study co-leader Edward E. Morrisey, PhD, a professor of Cardiovascular Medicine in the Perelman School of Medicine at the University of Pennsylvania. “The trick was how to direct the gene-editing machinery to target cells that line the airways of the lungs.”
The researchers showed that precisely timed in utero delivery of CRISPR gene-editing reagents to the amniotic fluid during fetal development resulted in targeted changes in the lungs of mice. They introduced the gene editors into developing mice four days before birth, which is analogous to the third trimester in humans.
The cells that showed the highest percentage of editing were alveolar epithelial cells and airway secretory cells lining lung airways. In 2018, a team led by Morrisey identified the alveolar epithelial progenitor (AEP) lineage, which is embedded in a larger population of cells called alveolar type 2 cells. These cells generate pulmonary surfactant, which reduces surface tension in the lungs and keeps them from collapsing with every breath. AEPs are a stable cell type in the lung and turn over very slowly, but replicate rapidly after injury to regenerate the lining of the alveoli and restore gas exchange.
In a second experiment, the researchers used prenatal gene editing to reduce the severity of an interstitial lung disease, surfactant protein C (SFTPC) deficiency, in a mouse model that has a common disease-causing mutation found in the human SFTPC gene. One hundred percent of untreated mice with this mutation die from respiratory failure within hours of birth. In contrast, prenatal gene editing to inactivate the mutant Sftpc gene resulted in improved lung morphology and survival of over 22 percent of the animals.
Future studies will be directed toward increasing the efficiency of the gene editing in the epithelial lining of lungs as well as evaluating different mechanisms to deliver gene editing technology to lungs. “Different gene editing techniques are also being explored that may one day be able to correct the exact mutations observed in genetic lung diseases in infants,” Morrisey said.
The Latest on: Gene editing
via Google News
The Latest on: Gene editing
- Mark Buchanan: Gene editing might alter our DNA. It might destroy our humanity tooon November 29, 2019 at 6:09 pm
Biologists recently revealed a new form of the gene-editing tool known as CRISPR that allows researchers to make precise changes to almost any element of DNA, permanently altering cellular ...
- 1 year later, mystery surrounds China’s gene-edited babieson November 29, 2019 at 5:23 pm
FILE - In this Nov. 28, 2018, file photo, He Jiankui, a Chinese researcher, speaks during the Human Genome Editing Conference in Hong Kong. Chinese scientist He Jiankui shocked the world by claiming ...
- CRISPR-Switch regulates sgRNA activity by Cre recombination for sequential editing of two locion November 29, 2019 at 2:21 am
Furthermore, we design sequential CRISPR-Switch-based editing of two loci in a strictly programmable manner and determined the order of mutagenic events that leads to development of glioblastoma in ...
- Gene editing kills malaria carrying mosquitoeson November 28, 2019 at 2:45 am
Researchers in England wipe out a population of malaria carrying mosquitoes in a laboratory using gene editing, raising renewed hopes of eradicating the disease in the wild. Stuart McDill reports.
- Mystery still surrounds gene-edited babies and Rice connectionon November 27, 2019 at 5:46 pm
“Nothing has changed,“ said Dr. Kiran Musunuru, a University of Pennsylvania geneticist who just published a book about gene editing and the CRISPR babies case. “I think we’re farther from governing ...
- High efficacy full allelic CRISPR/Cas9 gene editing in tetraploid potatoon November 27, 2019 at 3:26 am
Highly increased editing efficiencies in the Granular Bound Starch Synthase gene at the protoplast level were obtained by replacement of the Arabidopsis U6 promotor, driving expression of the CRISPR ...
- Is CRISPR Therapeutics the Best Gene-Editing Stock Right Now?on November 26, 2019 at 12:35 pm
CRISPR Therapeutics (NASDAQ:CRSP) made news recently after unveiling some impressive results for its signature gene-editing drug, CTX001. Coupled with an earlier analyst upgrade from Oppenheimer, the ...
- Genomics ETFs Surge on CRISPR's Gene Editing Progresson November 26, 2019 at 7:51 am
Notably, the studies were evaluating the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders — sickle cell disease (SCD) and adult transfusion-dependent b-thalassemia (TDT). CRISPR ...
- CRISPR gene-editing treatment shows success in first human patientson November 20, 2019 at 8:23 am
In sickle cell disease, red blood cells take on a sickle shape, which can cause clotting and pain. An investigational therapy using the revolutionary gene-editing technology CRISPR has shown promising ...
- Early results of CRISPR gene-editing treatment shows promise in first human trialson November 20, 2019 at 6:44 am
Officials from Vertex Pharmaceuticals and CRISPR Therapeutics have announced that preliminary results from testing CRISPR gene-editing treatment in human patients with blood disorders show promise ...
via Bing News